NEK1 and cancer: Our study was designed and conducted with a conclusion premised upon the notion that silencing LINC00883 could enhance the negative regulation of NEK1 by miR-136 and effectively reduce the malignant tumor characteristics of glioma, while reducing the risk of drug resistance.